- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
**Financial Highlights:** Cipla reported revenues of INR 7,073 Cr for Q3FY25, marking an 8% increase year-over-year. EBITDA stood at INR 1,989 Cr, a 16% rise, with a margin of 28.1%. Net profit surged 50% to INR 1,571 Cr, reflecting strong operational efficiency.
**Strategic Initiatives and Growth Drivers:** The company is focused on expanding its portfolio in chronic therapies, with a chronic revenue mix now at 61.5%. Notable approvals include the inhaled insulin Afrezza for diabetes management and the antibiotic Zemdri, both aimed to cater to unmet medical needs.
**Business Developments:** Cipla continued to strengthen its North American footprint, achieving a 21% share in the U.S. Albuterol market and rolling out 18 new product launches.
**Market Position and Competitive Advantage:** Cipla retained its #2 position in the Indian prescription market, supported by leading therapies in respiratory and urology. The South African market showed resilient performance, growing significantly quicker than the overall market.
**Investor Implications:** With robust financial growth and ongoing strategic initiatives, Cipla shows a positive outlook for sustained performance. Investors should watch for the company's continued ability to capitalize on new product launches and market presence.